Regeneron Reports Results from the P-I/II (CHORD) Study of DB-OTO for Hearing Loss
Shots:
- The P-I/II (CHORD) dose escalation & expansion study assesses DB-OTO’s safety, tolerability & efficacy to treat otoferlin mutated hearing loss. The trial is currently recruiting children in the US, UK & Spain
- The therapy in 1st patient (16mos.) showed an improvement of avg. 84 dB from baseline with 1 frequency measure achieving 10 dB in hearing level per PTA & avg. 80 dB improvement from baseline at all tested frequencies. ABR responses achieved a 45 dB frequency at the 24wks.
- The 2nd patient (4yrs.) had an improvement of avg. 19 dB from baseline with 1 frequency measure achieving 80 dB in hearing level per PTA & avg. 16 dB improvement from baseline at all tested frequencies. ABR responses achieved a 75 dB frequency at 6wks.
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron and Mammoth Collaborate for CRISPR Gene Editing Therapies Against Multiple Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
